Review: Low-molecular-weight heparin is effective and safe in the acute coronary syndromes

November 2003
ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58
Academic Journal
This article focuses on the usage of low-molecular-weight heparins (LMWH) in the management of acute coronary artery syndromes (ACS) and percutaneous coronary intervention. Selected studies have included randomized controlled trials that have compared LMWH with unfractionated heparin (UFH) or placebo for ACS. 4 large RCTs compared LMWH with UFH in unstable angina/non-ST-elevation myocardial infarction, 2 of these RCTs showed that enoxaparin was more effective than UFH at 14 days for the combined endpoint of death, MI, and recurrent ischemia with or without revascularization.


Related Articles

  • Review: Low-molecular-weight herapin is effective and safe in the acute coronary syndromes: COMMENTARY. Hillegass, William B.; Brott, Brigitta C. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58 

    Researcher G.C. Wong and colleagues have provided a systematic review of trials comparing low molecular weight heparin (LMWH) and un-fractionated heparin (UFH) in patients with acute coronary syndrome (ACS). In patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI),...

  • Review: Low-molecular-weight heparin is more effective than unfractionated heparin for preventing reinfarction in STEMI.  // ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p9 

    The article presents a study which states that for the prevention of reinfarction in ST-elevation acute myocardial infarction low-molecular-weight heparin (LMWH) is more effective than unfractionated heparin (UFH). As compare to the UFH group, LMWH group has lower chances of myocardial...

  • Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Mechanical Intervention for Acute Myocardial Infarction. Antoniucci, David // Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jul2005, Vol. 3 Issue 3, p173 

    Limitations in study designs and adoption of rigid criteria for randomization in clinical trials on acute myocardial infarction (AMI) may result in the enrolment of artificial populations, and subsequent trial results may be misleading in many ways rendering problematic the generalization of the...

  • Estrogen doesn't protect against heart disease, but….  // Contemporary OB/GYN;Apr2006, Vol. 51 Issue 4, p14 

    Reports on the results of a research conducted by the Women's Health Initiative, regarding the health impacts of unopposed equine estrogen between women aged 50 to 70 in the U.S. in 2006. Involvement of an estimated 10,000 older women in the study; Occurrence of 201 coronary diseases in a group...

  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Velazquez, Eric J.; Pfeffer, Marc A.; McMurray, John V.; Maggioni, Aldo P.; Rouleau, Jean-Lucien; Van de Werf, Frans; Kober, Lars; White, Harvey D.; Swedberg, Karl; Leimberger, Jeffrey D.; Gallo, Paul; Sellers, Mary Ann; Edwards, Susan; Henis, Marc; Califf, Robert M.; VALIANT Investigators, for the // European Journal of Heart Failure;Aug2003, Vol. 5 Issue 4, p537 

    Background: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or...

  • Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study. Schmiegelow, Michelle D.; Pedersen, Ole D.; Køber, Lars; Seibæk, Marie; Abildstrøm, Steen Z.; Torp-Pedersen, Christian // BMC Cardiovascular Disorders;2011, Vol. 11 Issue 1, p19 

    Background: We examined the incidence of new-onset atrial fibrillation in patients with left ventricular dysfunction. Patients either had a recent myocardial infarction (with or without clinical heart failure) or symptomatic heart failure (without a recent MI). Patients were with and without...

  • Direct thrombin inhibitor therapy in the cardiovascular patient. Chesebro, James H. // American Journal of Health-System Pharmacy;10/15/2003, Vol. 60 Issue 20, pS19 

    Direct thrombin inhibitors in cardiovascular patients are discussed. Patients presenting with acute coronary syndromes (ACS) of ST- and non-ST-segment elevation myocardial infarction (STEMI and NSTEMI, respectively) or unstable angina develop mural thrombi within minutes of plaque disruption or...

  • ANTICOAGULANT THERAPY TODAY. Vigran, I. Myron // Angiology;Jan1964, Vol. 15 Issue 1, p1 

    A review has been presented of some of the more classical and recent findings in regard to results of anticoagulant therapy in acute myocardial infarction, the long-term prophylactic treatment of coronary artery disease, the use of anticoagulant therapy in cerebral vascular disease, as well as...

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics